KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA
KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA MAHWAH, NJ – November 10, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical t
How this was made
The 30-second read
Why it matters
The Q3 earnings release shows a turnaround to profitability and a slight upward revision to full‑year revenue guidance, which may attract short‑term buying interest.
Market read
First‑report earnings with improved profitability and guidance raise the stock's short‑term appeal.
What to watch
Potential headwinds from competitive European tender market and reliance on a single distributor.
Background
KRMD is a Nasdaq‑listed medical‑technology company focused on large‑volume subcutaneous infusion solutions.
Ticker impact
KRMD reported Q3 2026 results with positive net income, adjusted EBITDA and revised revenue guidance to $48.0‑$48.5M.
likely upward pressure as investors price in the updated guidance and profitability turnaround
First‑report earnings release with better‑than‑expected profit and a modest upward revision to full‑year revenue guidance.
Market effects
Positive earnings may boost sentiment in the niche medical‑technology subcutaneous infusion sector.
Limited to U.S. and European markets where KRMD operates.
Low global impact; primarily a micro‑cap specific move.
Counterpoint
The modest revenue growth and small absolute numbers may limit upside; investors could be cautious.
Key entities
- ExecutiveAdam Kalbermatten
President and CEO of KRMD who commented on the results.